General Objectives
The aim of the National Haemoglobinopathy Panel (NHP) Cellular Therapy Group is to provide a national forum for discussion of specific transplant and cellular therapy (CT) issues for adult and paediatric patients approved by the NHP, or other commissioning eligibility, to proceed to hematopoietic stem cell transplantation (HSCT) and cellular therapies. This operational group aims to create harmonisation of protocols for adult and paediatric recipients, create a forum for data collection, case/outcomes reviews, and drive scientific research relating to stem cell transplant and cellular therapies. The Group is accountable to, and reports into the NHP.
The CTG leadership is formed of NHP Chair (Dr Kate Gardner) and a CRG lead/representative (Dr Subarna Chakravorty) as executive Co-Chairs, as well as three clinical cohort leads covering adult sickle cell disorder (Dr Victoria Potter), adult thalassaemia (Dr Ben Carpenter), and paediatrics (Professor Josu de la Fuente).
The CTG group meets once every month and attendees include other transplant/cellular therapy physicians, red cell clinicians, HCC clinical representatives and CNS representatives from all regions. All of whom are vital contributors to the workings of the CTG.
Patient Discussions
The CTG also carry out in-depth cellular therapy-focussed matters relating to specific patients who are either referred from the main NHP MDT in need of more CT-based review, or patients currently undergoing CT who need input from specialist haemoglobinopathy transplant/CT experts. The latter referrals are usually submitted by referred by the responsible transplant teams.
gstt.haemoglobinpanel@nhs.net
There are no articles at this time
